Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Merck Sharp & Dohme LLC.
The introduction of immune checkpoint inhibitors (ICIs) into the treatment of non-small cell lung cancer (NSCLC) has changed the treatment paradigm and become the standard of care in advanced stage lung cancer. Recent and ongoing efforts to replicate the remarkable success of immunotherapy with ICIs and biomarker-guided targeted therapy in advanced/metastatic NSCLC to the management of early-stage NSCLC have broken through the lull in the therapeutic landscape in this setting. The ICIs atezolizumab, durvalumab, and nivolumab have gained FDA approval for early-stage NSCLC indications. These additions to the treatment toolbox offer opportunities to delay recurrence and improve clinical outcomes for patients with this challenging malignancy.
Hear Drs. Gainor and Sands discuss their approach to these patients in this interactive Twitter and video presentation that will focus on improving the utilization of immunotherapy for neoadjuvant and adjuvant treatment, including a patient case study.
Justin F. Gainor, MD
Associate Professor of Medicine
Harvard Medical School
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Termeer Center for Targeted Therapies
Jacob M. Sands, MD
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Aakash Desai, MD, MPH
Hematology Oncology Fellow
Balazs Halmos, MD
Professor, Departments of Oncology and Medicine
Albert Einstein College of Medicine
Bronx, New York
Shruti Rajesh Patel, MD
Fellow, Department of Oncology
Stanford Health Care
This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists and other clinicians who treat and manage patients with lung cancer.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of December 15, 2022 through March 15, 2023, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Justin F. Gainor, MD, has reported no financial relationships or relationships to products or devices with ineligible companies.
Aakash Desai, MD, MPH, has reported no financial relationships or relationships to products or devices with ineligible companies.
Balazs Halmos, MD
Research Fees (to Institutions): AbbVie, Advaxis, Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Janssen, Merck, Pfizer
Consultant: Apollomics, Arcus, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Janssen, Merck Sharp & Dohme, LLC, Pfizer, Takeda, Turning Point Therapeutics, Veracyte
Shruti Rajesh Patel, MD, has reported no financial relationships or relationships to products or devices with ineligible companies.
Jacob M. Sands, MD
Consultant: AstraZeneca, Daiichi-Sankyo, Jazz Pharmaceuticals, Medtronic, PharmaMar, Sanofi, Takeda
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.